BRISBANE, Calif., May 31, 2017 (GLOBE NEWSWIRE) -- KaloBios Pharmaceuticals, Inc. (OTC:KBIO), a biopharmaceutical company focused on advancing
medicines for patients with neglected and rare diseases, announced today that Cameron Durrant, MD, chairman and CEO, will present a
company overview at two investor conferences in early June.
Details of the presentations follow:
Primary Capital, The Investor Conference
Date: Sunday, June 4, 2017
Location: The Resort at Pelican Hill, Newport Beach, Calif.
7th Annual LD Micro Invitational
Date: Tuesday, June 6, 2017, 1:30 p.m. PT
Track: 5
Location: Luxe Sunset Boulevard Hotel, Los Angeles, Calif.
In addition, senior management will hold one-on-one meetings at the conferences. To schedule a meeting, contact MZ Group at
mike.cole@mzgroup.us.
About KaloBios Pharmaceuticals, Inc.
KaloBios Pharmaceuticals, Inc. (OTC:KBIO) is an emerging biopharmaceutical company focused on advancing medicines for patients
with neglected and rare diseases through innovative and responsible business models. Lead compounds in the KaloBios portfolio are
benznidazole for the potential treatment of Chagas disease in the U.S., and the proprietary monoclonal antibodies, lenzilumab and
ifabotuzumab. Lenzilumab has potential for treatment of various rare diseases, including hematologic cancers such as chronic
myelomonocytic leukemia (CMML) and potentially juvenile myelomonocytic leukemia (JMML). For more information, visit www.kalobios.com.
CONTACT: Investors: Mike Cole O: 949-259-4988 C: 949-444-1341 mike.cole@mzgroup.us Media: Lisa Guiterman O: 301-217-9353 C: 202-330-3431 media@kalobios.com
